EPANUTIN 250mg/5ml price in UAE

Overview

Welcome to Dwaey, specifically on EPANUTIN 250mg/5ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Phenytoin sodium.
EPANUTIN 250mg/5ml is available in the market in concentration 250mg/5ml and in the form of Injection/Solution for.

PARKE DAVIS & C0 LIMITED is the producer of EPANUTIN 250mg/5ml and it is imported from UK, The most popular alternatives of EPANUTIN 250mg/5ml are listed downward .

Mode Of Action

Phenytoin acts as an anticonvulsant by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses; thus stabilising neuronal membranes and decreasing seizure activity. It acts as an antiarrhythmic by extending the effective refractory period and suppressing ventricular pacemaker automaticity, shortening action potential in the heart.

Indication

Epilepsy
Tonic-clonic status epilepticus

Precaution

Cardiovascular disease, e.g. sinus bradycardia, heart blocks; DM; hepatic impairment; hypoalbuminemia; porphyria; seizures (may increase frequency of petit mal seizures); debilitated patients; elderly. Caution in IV admin in hypotension, heart failure or MI, monitor BP and ECG during therapy. IV must be given slowly (too rapid admin may cause hypotension, CNS depression, cardiac arrhythmias and impaired heart conduction). Extravasation and intra-arterial admin must be avoided. Do not discontinue abruptly (may increase seizure frequency), unless safety concerns require a more rapid withdrawal. May impair ability to drive or operate machinery. Lactation: Excreted in breast milk; not recommended

Side Effects

Hypersensitivity
lack of appetite
headache
dizziness
tremor
transient nervousness
insomnia
GI disturbances (e.g. nausea
vomiting
constipation)
tenderness and hyperplasia of the gums
acne
hirsutism
coarsening of the facial features
rashes
osteomalacia. Phenytoin toxicity as manifested as a syndrome of cerebellar
vestibular
ocular effects
notably nystagmus
diplopia
slurred speech
and ataxia; also with mental confusion
dyskinesias
exacerbations of seizure frequency
hyperglycaemia. Solutions for inj may cause local irritation or phlebitis. Prolonged use may produce subtle effects on mental function and cognition
especially in children. Potentially Fatal: Toxic epidermal necrolysis
Stevens-Johnson syndrome.

Contra indication

Pregnancy. IV admin in sinus bradycardia, heart block, or Stokes-Adams syndrome.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Interaction

Effects with other sedative drugs or ethanol may be potentiated. Enhances toxic effects of paracetamol, lithium. Increased risk of osteomalacia with acetazolamide. Decreased serum levels/effects with acyclovir, antineoplastics, benzodiazeines, ciprofloxacin, CYP2C9 inducers (e.g. carbamazepine), CYP2C19 inducers (e.g. rifampin), folic acid, vigabatrin. Increased serum concentrations with allopurinol, capecitabine, cimetidine, CYP2C9 inhibitors (e.g. fluconazole), CYP2C19 inhibitors (e.g. delavirdine), disulfiram, methylphenidate, metronidazole, omeprazole, SSRI, trazodone, trimethoprim. Increases metabolism of antiarrhythmics, anticonvulsants, antipsychotics, beta-blockers, calcium channel blockers, chloramphenicol, corticosteroids, doxycycline, oestrogens, HMG-CoA reductase inhibitors, methadone, theophylline, TCAs. Decreases levels/effects of clozapine, ciclosporin, tacrolimus, CYP2B6 substrates (e.g. bupropion, selegiline), CYP2C8 substrates (e.g. amiodarone), CYP2C9 substrates (e.g. celecoxib), CYP2C19 substrates (e.g. citalopram), CYP3A4 substrates (e.g. benzodiazepines), digoxin, itraconazole, levodopa, neuromuscular-blocking agents, thyroid hormones, topiramate. Increases levels/effect of dopamine, ticlopidine. Valproic acid may displace phenytoin from binding sites; and affect phenytoin serum concentrations. Transiently increases the hypothrombinaemia response to warfarin initially, followed by an inhibition of the response. Potentially Fatal: Enhances the hypotensive properties of dopamine and the cardiac depressant properties of lidocaine.